Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Unguided De-Escalation Strategy From Potent P2Y12 Inhibitors in Patients Presented With ACS: When, Whom and How?

  • Jin Sup Park (Department of Cardiology and Medical Research Institute, Pusan National University Hospital) ;
  • Young-Hoon Jeong (CAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University School of Medicine)
  • Received : 2022.02.03
  • Accepted : 2022.02.08
  • Published : 2022.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289-367. https://doi.org/10.1093/eurheartj/ehaa575
  2. Kupka D, Sibbing D. De-escalation of P2Y12 receptor inhibitor therapy after acute coronary syndromes in patients undergoing percutaneous coronary intervention. Korean Circ J 2018;48:863-72. https://doi.org/10.4070/kcj.2018.0255
  3. Tavenier AH, Mehran R, Chiarito M, et al. Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with ACS: a meta-analysis. Eur Heart J Cardiovasc Pharmacother 2021:pvab068.
  4. Ki YJ, Lee BK, Park KW, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with STEMI. Korean Circ J 2022;52:304-19. https://doi.org/10.4070/kcj.2021.0293
  5. van der Sangen NMR, Rozemeijer R, Chan Pin Yin DRPP, et al. Patient-tailored antithrombotic therapy following percutaneous coronary intervention. Eur Heart J 2021;42:1038-46. https://doi.org/10.1093/eurheartj/ehaa1097
  6. Smits PC, Frigoli E, Tijssen J, et al. Abbreviated antiplatelet therapy in patients at high bleeding risk with or without oral anticoagulant therapy after coronary stenting: an open-label, randomized, controlled trial. Circulation 2021;144:1196-211. https://doi.org/10.1161/CIRCULATIONAHA.121.056680
  7. Watanabe H, editor. STOPDAPT-2 ACS: one-month dual antiplatelet therapy followed by clopidogrel monotherapy in acute coronary syndrome. ESC Congress; 2021 Aug 27-30.
  8. Kim HK, Tantry US, Park HW, et al. Ethnic difference of thrombogenicity in patients with cardiovascular disease: a pandora box to explain prognostic differences. Korean Circ J 2021;51:202-21. https://doi.org/10.4070/kcj.2020.0537
  9. Jeong YH, Oh JH, Yoon HJ, et al. Pharmacodynamic profile and prevalence of bleeding episode in East Asian patients with acute coronary syndromes treated with prasugrel standard-dose versus de-escalation strategy: a randomized A-MATCH trial. Thromb Haemost 2021;121:1376-86. https://doi.org/10.1055/a-1346-3300
  10. Lee SH, Kim HK, Jeong MH, et al. Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention. Eur Heart J Cardiovasc Pharmacother 2021;7:112-24. https://doi.org/10.1093/ehjcvp/pvaa005